Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100 million, co‑led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science & Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company’s national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.
Financing Details
Item
Detail
Company
Jiangsu Trulive Medical
Round
Series C
Amount
Over RMB 100 million
Lead Investors
Oriental Fortune Capital, Guoyuan Equity
Co‑Investors
Xiamen Industry Investment/Venture Capital, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science & Technology Innovation
Existing Shareholder
Lifetree Capital
Founded
2019
Use of Proceeds
Deploy national base network, R&D core, manufacturing cluster, production bases
Flagship Products:Mitral and tricuspid valve therapies
Market Need: Cardiovascular diseases have extremely high mortality and disability rates with limited domestic solutions
Competitive Moat:Differentiated advantage in mitral/tricuspid valve tracks vs. competitors focused on aortic valves
Strategic Deployment Plan
Region
Function
Timeline
Shanghai
R&D core
Established
Yangtze River Delta
High‑end manufacturing cluster
2026‑2027
Key Regions
R&D and production bases
2027‑2028
Objective
National coverage via multi‑base synergy
Full deployment by 2028
Market Impact & Outlook
Metric
Value
China Structural Heart Disease Market
¥15 billion (2024)
Mitral/Tricuspid Valve Segment
¥3.5 billion; growing 25% CAGR
Addressable Patient Pool
~500,000 patients eligible for mitral/tricuspid intervention
Revenue Forecast
¥800 million‑1.2 billion by 2030
Market Share Target
15‑20% of mitral/tricuspid segment
Manufacturing: Multi‑base strategy enables local production, reducing costs and improving supply chain resilience
Regulatory Path: Class III medical device pathway; key products in late‑stage clinical trials
Next Catalyst: First mitral valve product launch expected H2 2026
Forward‑Looking Statements This brief contains forward‑looking statements regarding Trulive Medical’s financing utilization, product launch timelines, and market penetration. Actual results may differ materially due to risks including regulatory approvals, competitive responses, and execution of multi‑base strategy.-Fineline Info & Tech
By Fineline Cube 